BioCryst Pharmaceuticals, Inc. (BCRX)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 2
Do Nothing: technicalScore 2/5 — price 7.667 is below SMA20 7.96, SMA50 8.28 and SMA200 8.80 with MACD -0.18 and ADX 15.5, a post-earnings base rather than a bullish setup; no pullback/oversold limit qualifies (trend-alignment gate: price < SMA50 with MACD < 0, and price < a declining SMA200 with SMA50 < SMA200 and no momentum reclaim) and no breakout stop qualifies (a buy stop above the settled 7.83 base high, with stop 7.39 and R/R 1.56, would only chase a weak downtrend base on a chart scoring below the 3/5 entry floor).
Company overview
BioCryst Pharmaceuticals, Inc. is a biotechnology company specializing in the development of orally administered small-molecule therapeutics. It markets Peramivir injection for influenza and ORLADEYO for hereditary angioedema. The company also has a pipeline of candidates for various diseases and collaborates with several pharmaceutical and governmental organizations.
Fundamental
fairBioCryst's fundamentals are mixed, with cash generation overshadowed by a complex balance sheet and event-driven earnings.
BioCryst is a commercial-stage rare-disease company whose ORLADEYO franchise is growing again and whose operations now generate cash, but the reported figures are dominated by two one-time items - a $244M European licensing gain in 2025 and a $697.8M non-cash acquired-IPR&D charge in 2026 - that make both the trailing profit and the trailing loss misleading. Underneath, the business is roughly break-even to modestly profitable on a recurring basis, against a heavily levered balance sheet (negative book equity, ~$828M of debt including royalty obligations), 20% dilution in nine months, and a litigated core patent. Mixed, event-driven setup rather than a clean fundamental story.
Sentiment
fairSentiment is constructive but post-event, with no immediate catalysts to drive action.
An announced, market-rewarded Q3 2026 beat (revenue $180.3M, ORLADEYO $174.8M, FY26 revenue guidance raised to $715-730M) sitting on top of a regulator-confirmed ORLADEYO 150 mg oral-pellet label expansion anchors a constructive but distinctly post-event setup; the sentiment delta is indeterminate because the baseline pull came back degraded and, after de-duplication, held only two unique routine items, and retail is unreadable after a Reddit 403 block. Red-Flag Screen clean with no cap applied, but with the anchoring catalyst eight days old, only partially priced, and no forward-dated driver on the calendar, the setup stays in forming territory rather than the top band.
Technical
weakTechnical indicators show a weak setup with price below key moving averages and no bullish momentum.
BCRX scores 2/5: price 7.67 sits below the entire moving-average stack — SMA20 7.96, SMA50 8.28, SMA200 8.80, EMA9 7.80, EMA21 7.97, WMA9 7.73, WMA21 7.93 and DEMA14 7.70 — a uniformly bearish trend frame, with MACD negative and rolling over (line -0.18, signal -0.14, histogram -0.04), RSI14 41.7 (mid-range weak) and ADX14 15.5 confirming no directional trend. The only constructive evidence is a six-session 7.38–7.83 base after the 5 Nov earnings gap, Williams %R -80.6 (oversold) and today's intraday reversal off 7.46 to close 7.667 near the top of the range; that is bounce-only consolidation, not a tradable bullish setup, so the chart scores 2 and no tradable setup is classified.
You’re looking at 2026-11-12 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

